Day three of SABCS 20 kicks off this morning with General Session 3, featuring abstract presentations covering some of the latest results in cancer research along with commentaries from expert discussants, followed by six Spotlight Sessions this afternoon.
In one of two SABCS 20 Plenary Lectures, Elizabeth A. Mittendorf, MD, PhD, discussed local regional therapy considerations after neoadjuvant chemotherapy and summarized some of the key “knowns” and “unknowns” related to the topic.
Like most major medical conferences planned for 2020, SABCS kicked off in an all-virtual platform. Just as the meeting adapted to these challenging times, so too must cancer research, said Norman E. Sharpless, MD.
The antibody landscape is shifting. After years of using antibodies as therapeutic agents, they are being re-purposed as targeted vehicles to deliver highly toxic payloads to specific cell surface antigens.
Extended follow-up data from the phase III monarchE trial showed that adding the CDK inhibitor abemaciclib to standard adjuvant endocrine therapy continued to improve invasive disease-free survival among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer.